Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma, Non-Small-Cell Lung

Sarcoma

Carcinoma, Renal Cell

Lung Neoplasms

Kidney Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Renal Cell Carcinoma

Soft Tissue Sarcoma

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Sorafenib

Panobinostat

Protein Kinase Inhibitors

Enzyme Inhibitors

Histone Deacetylase Inhibitors

Expansion A -RCC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.

Expansion B -NSCLC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.

Expansion C -STS cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.

Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.

Panobinostat (LBH589), Sorafenib

Harry Drabkin, MD

The purpose of this study is to determine if a new investigational drug called Panobinostat is safe, tolerable and to obtain an initial assessment of efficacy, when given in combination with Sorafenib for the treatment of certain types of lung cancer, kidney cancer and soft tissue sarcoma.

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

A Phase I Safety and Tolerability Study of LBH589 in Combination With Sorafenib in Patients With Advanced Renal Cell Carcinoma, Soft Tissue Sarcoma, and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies.

Novartis Pharmaceuticals

Medical University of South Carolina

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers	NCT01005797	Renal Cancer Non Small Cell ... Soft Tissue Sar...	Panobinostat (L...	18 Years -	Medical University of South Carolina
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers	NCT01005797	Renal Cancer Non Small Cell ... Soft Tissue Sar...	Panobinostat (L...	18 Years -	Medical University of South Carolina

Spots Global Cancer Trial Database for panobinostat (lbh589), sorafenib